Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

133 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cost-effectiveness of trifluridine/tipiracil as a third-line treatment of metastatic gastric cancer, including adenocarcinoma of the gastrohesophageal junction, among patients previously treated in Greece.
Gourzoulidis G, Koulentaki M, Koumarianou A, Samadas E, Androulakis N, Xynogalos S, Papakotoulas P, Boukovinas I, Karamouzis M, Souglakos J, Chotzagiannoglou V, Beletsi A, Kourlaba G. Gourzoulidis G, et al. Among authors: boukovinas i. Expert Rev Pharmacoecon Outcomes Res. 2022 Mar;22(2):259-269. doi: 10.1080/14737167.2021.1921576. Epub 2021 May 6. Expert Rev Pharmacoecon Outcomes Res. 2022. PMID: 33900864
Combination of irinotecan (CPT-11) plus oxaliplatin (L-OHP) as first-line treatment in locally advanced or metastatic gastric cancer: a multicentre phase II trial.
Souglakos J, Syrigos K, Potamianou A, Polyzos A, Boukovinas I, Androulakis N, Kouroussis Ch, Vardakis N, Christophilakis Ch, Kotsakis A, Georgoulias V. Souglakos J, et al. Among authors: boukovinas i. Ann Oncol. 2004 Aug;15(8):1204-9. doi: 10.1093/annonc/mdh312. Ann Oncol. 2004. PMID: 15277259 Free article. Clinical Trial.
Front-line treatment of advanced non-small cell lung cancer with irinotecan and docetaxel: a multicentre phase II study.
Ziotopoulos P, Androulakis N, Mylonaki E, Chandrinos V, Zachariadis E, Boukovinas I, Agelidou A, Kentepozidis N, Ignatiadis M, Vossos A, Georgoulias V; Lung Cancer Committee of the Hellenic Oncology Research Group (HORG). Ziotopoulos P, et al. Among authors: boukovinas i. Lung Cancer. 2005 Oct;50(1):115-22. doi: 10.1016/j.lungcan.2005.05.004. Lung Cancer. 2005. PMID: 15993981 Clinical Trial.
Sequential gemcitabine and cisplatin followed by docetaxel as first-line treatment of advanced urothelial carcinoma: a multicenter phase II study of the Hellenic Oncology Research Group.
Boukovinas I, Androulakis N, Vamvakas L, Papakotoulas P, Ziras N, Polyzos A, Kalykaki A, Kotsakis A, Xenidis N, Gioulmbasanis I, Mavroudis D, Georgoulias V. Boukovinas I, et al. Ann Oncol. 2006 Nov;17(11):1687-92. doi: 10.1093/annonc/mdl286. Epub 2006 Sep 12. Ann Oncol. 2006. PMID: 16968872 Free article. Clinical Trial.
Docetaxel versus docetaxel plus gemcitabine as front-line treatment of patients with advanced non-small cell lung cancer: a randomized, multicenter phase III trial.
Georgoulias V, Androulakis N, Kotsakis A, Hatzidaki D, Syrigos K, Polyzos A, Agelidou A, Varthalitis I, Ziras N, Agelidou M, Chandrinos V, Boukovinas I, Geroyianni A, Vamvakas L, Mavroudis D. Georgoulias V, et al. Among authors: boukovinas i. Lung Cancer. 2008 Jan;59(1):57-63. doi: 10.1016/j.lungcan.2007.07.021. Epub 2007 Aug 31. Lung Cancer. 2008. PMID: 17765354 Clinical Trial.
Gemcitabine plus oxaliplatin (GEMOX) in pretreated patients with advanced ovarian cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG).
Kalykaki A, Papakotoulas P, Tsousis S, Boukovinas I, Kalbakis K, Vamvakas L, Kotsakis A, Vardakis N, Papadopoulou P, Georgoulias V, Mavroudis D; Hellenic Oncology Research Group. Kalykaki A, et al. Among authors: boukovinas i. Anticancer Res. 2008 Jan-Feb;28(1B):495-500. Anticancer Res. 2008. PMID: 18383891 Free article. Clinical Trial.
Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine.
Souglakos J, Boukovinas I, Taron M, Mendez P, Mavroudis D, Tripaki M, Hatzidaki D, Koutsopoulos A, Stathopoulos E, Georgoulias V, Rosell R. Souglakos J, et al. Among authors: boukovinas i. Br J Cancer. 2008 May 20;98(10):1710-5. doi: 10.1038/sj.bjc.6604344. Epub 2008 Apr 15. Br J Cancer. 2008. PMID: 18414411 Free PMC article. Clinical Trial.
Pooled analysis of elderly patients with non-small cell lung cancer treated with front line docetaxel/gemcitabine regimen: the Hellenic Oncology Research Group experience.
Pallis AG, Polyzos A, Boukovinas I, Agelidou A, Lamvakas L, Tsiafaki X, Agelidou M, Pavlakou G, Chandrinos V, Kakolyris S, Christophyllakis C, Kentepozidis N, Giassas S, Androulakis N, Agelaki S, Georgoulias V. Pallis AG, et al. Among authors: boukovinas i. J Thorac Oncol. 2008 May;3(5):505-10. doi: 10.1097/JTO.0b013e31816b4b32. J Thorac Oncol. 2008. PMID: 18449003 Free article.
Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients.
Boukovinas I, Papadaki C, Mendez P, Taron M, Mavroudis D, Koutsopoulos A, Sanchez-Ronco M, Sanchez JJ, Trypaki M, Staphopoulos E, Georgoulias V, Rosell R, Souglakos J. Boukovinas I, et al. PLoS One. 2008;3(11):e3695. doi: 10.1371/journal.pone.0003695. Epub 2008 Nov 11. PLoS One. 2008. PMID: 19002265 Free PMC article.
FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG).
Polyzos A, Malamos N, Boukovinas I, Adamou A, Ziras N, Kalbakis K, Kakolyris S, Syrigos K, Papakotoulas P, Kouroussis C, Karvounis N, Vamvakas L, Christophyllakis C, Athanasiadis A, Varthalitis I, Georgoulias V, Mavroudis D. Polyzos A, et al. Among authors: boukovinas i. Breast Cancer Res Treat. 2010 Jan;119(1):95-104. doi: 10.1007/s10549-009-0468-0. Epub 2009 Jul 28. Breast Cancer Res Treat. 2010. PMID: 19636702 Clinical Trial.
133 results